Accreditation Information
Listen to Real Audio Round Table Discussion
Program Faculty
Bruce Lydiard, M.D., Chairman, Director of Southeast Health Consultants, Charleston, SC
Mark H. Pollack, M.D., Director, Anxiety Disorders Program, Massachusetts General Hospital, Associate Professor of Psychiatry, Harvard Medical School, Boston, MA
Terence A. Ketter, M.D., Director of the Bipolar Disorders Clinic, Stanford University, Palo Alto, CA
Ethan Kisch, M.D., Assistant Clinical Professor, Tufts University School of Medicine, Boston, MA, Psychiatrist in Private Practice, Providence, RI
Sponsor:
School of Medicine, Virginia Commonwealth University, Medical College of Virginia Campus (VCU), Richmond, VA
Scientific Advisor:
John M. Hettema, M.D., Ph.D., Associate Professor of Psychiatry, Medical College of Virginia of Virginia Commonwealth University.
Production services for this monograph:
KSP Communications, 140 Sherman St, 3rd Floor, Fairfield, CT 06430, (203) 259-2279.
Website Design and Development:
Chris Stephens
Jeanne Schlesinger, M.Ed.
Faculty Disclosure
In compliance with the Standards for Commercial Support of Continuing Medical Education (ACCME), the following faculty report these relationships:
Bruce Lydiard, M.D.: Research support: Bristol-Myers Squibb,
Pfizer, SmithKline Beecham, Wyeth-Ayerst, Forest, Glaxo Wellcome,
Parke-Davis, Eli Lilly, Interneuron, Roche, Solvay, Organon, and
Pharmacia & Upjohn. Supported presentations: Bristol-Myers
Squibb, Eli Lilly, SmithKline Beecham, Wyeth-Ayerst, Forest, Glaxo
Wellcome, Parke-Davis, Pharmacia & Upjohn, Ravizza, and
Hoechst. Consultant: Bristol-Myers Squibb, Pfizer, Eli Lilly,
SmithKline Beecham, Wyeth-Ayerst, Forest, Glaxo Wellcome,
Parke-Davis, Roche, DuPont, Organon, and AstraZeneca.
Mark H. Pollack, M.D.: Supported presentations: Bristol-Myers
Squibb, Forest, Eli Lilly, Parke-Davis, Pfizer, SmithKline Beecham,
Solvay, and Wyeth-Ayerst. Research support: Bristol-Myers Squibb, Forest, Eli Lilly, Parke-Davis, Pfizer, SmithKline Beecham, Solvay,
and Wyeth-Ayerst. Consultant: Eli Lilly, Parke-Davis, Pfizer,
SmithKline Beecham, and Wyeth-Ayerst.
Terence A. Ketter, M.D.: Research support: Abbott, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, and Janssen. Consultant: Abbott,
AstraZeneca, Bristol-Myers Squibb, Cephalon, Elan, Eli Lilly,
GlaxoSmithKline, Janssen, Novartis, and Shire. Supported
presentations: Abbott, Bristol-Myers Squibb, Eli Lilly,
GlaxoSmithKline, Janssen, and Novartis.
Ethan Kisch, M.D.: Physician Advisory Board/Consultant/Speakers'
Bureau: Abbott, Cephalon, Eli Lilly, Pfizer, GlaxoSmithKline,
AstraZeneca, Novartis, and Forest.
Accreditation and Educational Credit
This material is not designated for credit.
Statement of Educational Need
This activity is designed to respond to the needs of psychiatrists and other physicians who treat patients with anxiety and other neuro-psychiatric disorders by updating their knowledge of GABA-enhancing agents, which are emerging as potentially important agents in the
treatment of these disorders.
Educational Objectives
After reading this monograph, listening to the audio CD, and completing the post-test, the participant should be able to:
- Describe the historical background of the current treatment of anxiety disorders
- Describe the role of benzodiazepines in the treatment of anxiety disorders
- Better understand the role of GABA in the central nervous system
- Understand the rationale for using GABAergic drugs to treat anxiety and other neuropsychiatric disorders
- Understand the potential clinical utility of the newer, specific GABA-enhancing agents
Statement of Educational Method
The educational information is presented online in two separate pages, which cover the same material as the original 8-page written monograph. The original accompanying 30-minute audio CD is available online under the link "Round Table Discussion (Real Audio)"
Statement of Evaluation Instrument
A 12-question multiple-choice post-test is used as the evaluation instrument. An activity evaluation questionnaire will be completed by each participant.
Statement of Intended, or Target, Audience
This activity is intended for, but not limited to: psychiatrists and other physicians who care for patients with anxiety and other neuropsychiatric disorders.
Statement of Unlabeled Usage
The information presented in this activity is that of the presenters and
does not necessarily represent the views, and is independent of, Virginia
Commonwealth University and KSP Communications. Specific medicines
discussed in this monograph may not yet be specifically approved and/or
may not be specified to be used as indicated by the speakers. Before pre-scribing
any medication, the physician should review the complete pre-scribing
information, including indications, contraindications, warnings,
precautions, and adverse effects.
Instructions for CME Credit
This material is not designated for credit.
©Copyright 2001, Virginia Commonwealth University
Acknowledgement of Commercial Support
Supported by an unrestricted educational grant from Cephalon, Inc.
Listen to Real Audio Round Table Discussion
|
